Yongzi Xu

机构：Jiangsu Cancer Hospital, Nanjing Medical University · ORCID：0000-0003-0493-7178

发表论文 5 篇 · 总被引 116 次 · h-index 4

代表论文

• Long non‑coding RNA H19 is involved in sorafenib resistance in hepatocellular carcinoma by upregulating miR‑675 (2020 · Oncology Reports · 被引 46)
• UBE2S promotes cell chemoresistance through PTEN-AKT signaling in hepatocellular carcinoma (2021 · Cell Death Discovery · 被引 37)
• Adjuvant transarterial chemoembolization for hepatocellular carcinoma following curative resection: A randomized, open-label, phase 3 trial (2025 · Hepatology · 被引 28)
• Construction of a postoperative liver metastasis prediction model for colorectal cancer based on spectral CT imaging, CEA, and CA19-9 (2025 · Translational Cancer Research · 被引 3)
• Effects of S-1 single agent chemotherapy in the radical resection of cholangiocarcinoma (2015 · Zhōnghuá xiāohuà wàikē zázhì/Zhonghua xiaohua waike zazhi)